United States · FDA National Drug Code directory

Flucelvax

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
83703-088_547566e6-e167-be56-e063-6294a90af9f9
Product NDC
83703-088
Form
INJECTION, SUSPENSION
Composition / generic term
INFLUENZA A VIRUS A/Georgia/12/2022 CVR-167 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA A VIRUS A/Victoria/800/2024 CVR-289 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED), INFLUENZA B VIRUS B/Singapore/WUH4618/2021 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED)
Labeler
Bamboo US BidCo LLC
Marketing category
BLA
Marketing start / end (source format)
20260801
Source listing expiry
20271231

Source-listed ingredients

  • INFLUENZA A VIRUS A/GEORGIA/12/2022 CVR-167 (H1N1) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
  • INFLUENZA A VIRUS A/VICTORIA/800/2024 CVR-289 (H3N2) ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL
  • INFLUENZA B VIRUS B/SINGAPORE/WUH4618/2021 ANTIGEN (MDCK CELL DERIVED, PROPIOLACTONE INACTIVATED) — 15 ug/.5mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 10 SYRINGE, GLASS in 1 CARTON (83703-088-03) / .5 mL in 1 SYRINGE, GLASS (83703-088-04) · 83703-088-03

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →